The presence of a palpable mass is an independent predictor of microinvasion in Ductal Carcinoma in situ of the Breast
Abstract
Purpose: Breast cancer is the most common cancer among women worldwide. Ductal Carcinoma in situ (DCIS) is one of the most common types of these cancers. Factors associated with microinvasion still need to be investigated.
Materials and methods: In this retrospective study, we analyzed data from 70 female patients diagnosed with DCIS and managed at a tertiary center between 2011 and 2024. Demographic parameters, clinicopathological characteristics, and immunohistochemical findings of the patients were examined in comparison with their microinvasion status.
Results: 70 female patients with Ductal Carcinoma in situ, with a median age of 51 years, were investigated. Among these patients, 17 cases (24.3%) had microinvasion. Compared with demographic parameters, only BMI was associated with microinvasion status. Patients with higher BMI had lower risk of microinvasion (p=0.038).
The presence of a palpable mass was significantly higher in patients with microinvasion (p=0.001), suggesting a potential link between tumor palpability and invasion.
Immunohistochemical analysis demonstrated associations between hormone receptor status, HER2 expression, and microinvasion. The presence of HER2 was significantly associated with microinvasion (p=0.026). Multivariate analysis however, revealed that tumor palpability was the only independent factor associated with microinvasion status (Odds Ratio: 5.233; 1.339 - 20.455; p=0.017).
Conclusion: The presence of a palpable mass emerged as the only independent factor associated with microinvasion in DCIS.
Keywords
DCIS, palpable mass, microinvasion, breast cancer, sentinel iymph node
Project Number
E-60116787-020-604967
References
- Tomlinson Hansen SE, Khan M, Cassaro S. Breast ductal carcinoma in situ. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.statpearls.com. Accessed February 27, 2023
- Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):139-141. doi:10.1093/jncimonographs/lgq027
- Shiino S, Quinn C, Ball G, et al. Prognostic significance of microinvasion with ductal carcinoma in situ of the breast: a meta-analysis. Breast Cancer Res Treat. 2023;197(2):245-254. doi:10.1007/s10549-022-06800-3
- Stanciu Pop C, Nollevaux MC, Berlière M, et al. Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast. Virchows Arch. 2021;479(1):33-43. doi:10.1007/s00428-021-03040-6
- Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011;103(6):478-488. doi:10.1093/jnci/djr027
- Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-7720. doi:10.1200/JCO.2005.08.001
- Parker C, Damodaran S, Bland KI, Hunt KK. The breast. In: Brunicardi FC, Andersen DK, Billiar TR, et al., editors. Schwartz's principles of surgery. 11th ed. New York, NY: McGraw-Hill Education; 2019.
- Boler DE, Cabioglu N, Ince U, Esen G, Uras C. Sentinel lymph node biopsy in pure DCIS: is it necessary? ISRN Surg. 2012;2012:394095. doi:10.5402/2012/394095
- Julian TB, Land SR, Fourchotte V, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol. 2007;14(8):2202-2208. doi:10.1245/s10434-007-9353-4
- Aksoy SÖ, Sevinç Aİ, Güray M, Balcı P. Duktal karsinoma in situ'da sentinel lenf nodu biyopsisi gerekli midir? DEU Tıp Derg. 2017;31(3):147-151. doi:10.5505/deutip.2017.50023
